BioHedge Weekly

The Reporting Persons intend to review their investment in ImageneBio, Inc. based on various factors, including the Issuer's business, financial condition, and market conditions. They may acquire additional shares or dispose of existing shares in the open market or privately negotiated transactions.

Agreements · The Issuer entered into a registration rights agreement with April 2026 PIPE Investors, including RA Capital, to register for resale the April 2026 PIPE Shares and April 2026 Warrant Shares. The Issuer agreed to file a registration statement within 45 days of the April 2026 Private Placement closing and use best efforts to keep it effective until all Registrable Securities are resold or can be resold under Rule 144 without volume or manner-of-sale limitations.

BVF Partners L.P. entered into a Voting and Support Agreement with Ligand Pharmaceuticals Incorporated, agreeing to vote their shares in favor of the merger between XOMA and Ligand's subsidiary, Flex Merger Sub, Inc. They also agreed to convert their Series X Preferred Stock to common shares to facilitate voting and not to transfer their shares or assert appraisal rights.

Agreements · BVF Partners L.P. entered into a Voting and Support Agreement with Ligand Pharmaceuticals Incorporated, committing to vote their shares in favor of the merger and convert preferred stock to common shares for voting purposes. The agreement also includes provisions against transferring shares and waiving appraisal rights.